A peer-reviewed, online, open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community. Topics include target and antibody discovery, mechanistic research, new technologies and methods, manufacturing, clinical trials, regulation, policies, and more. Antibody Therapeutics article types include original research, reviews, cutting-edge technologies, new methods, news, interviews, and meeting highlights.
Scholar9.com is a peer-review platform that hosts journals from across the globe. Please note that we do not own any of the journals hosted on the platform.
Services for Journal Owners:
Our platform enables journal owners to send articles for peer review to users who have registered via https://scholar9.com/register and have consented to serve as reviewers for multiple journals. Additionally, we offer an indirect manuscript submission system for journals that are claimed and actively managed by their respective owners on Scholar9.com.
Indexing and Contact Detail:
For accurate information about the indexing status of journals (in databases such as UGC CARE, Scopus, or Web of Science) and contact details, users must refer to the respective official websites.
Limitations of Responsibility:
Scholar9 is not responsible for indexing claims, manuscript acceptance/rejection, refunds of article processing charges, or any stage of the final publication process. Users are strongly advised to verify all information provided on the platform independently.
Resolution of Disputes:
Scholar9.com disclaims liability for disputes related to indexing claims, publication decisions, or other journal-specific matters. Users are encouraged to contact the respective journal owners directly for detailed information and clarifications.
True scholar network
